API | r-amphetamine

r-amphetamine Report issue

Small molecule Experimental

AACT ChEMBL Drug Central KEGG PubChem

Active Ingredient History

NOW

LEVAMFETAMINE the levorotatory form of amphetamine. L-amphetamine, is a central nervous system (CNS) stimulant known to increase wakefulness and concentration in association with decreased appetite and fatigue. Pharmaceuticals that contain levoamphetamine are currently indicated and prescribed for the treatment of attention deficit hyperactivity disorder (ADHD), obesity, and narcolepsy in some countries. L-Amphetamine succinate was sold in Hungary between 1952 and 1955 under the brand name Cydril. ^NCATS

Chemistry

SMILES: C[C@@H](N)Cc1ccccc1
InChIKey: KWTSXDURSIMDCE-MRVPVSSYSA-N
Mol. Mass: 135.21
ALogP: 1.58 Partition coefficient
ChEMBL Molecules:

levamfetamine

levamfetamine succinate

More Chemistry

Pharmacology

Mechanism of Action:
- Synaptic vesicular amine transporter (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (2)

Attention Deficit Disorder with Hyperactivity (approved 1969)

Narcolepsy (approved 1969)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Schizophrenia (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue